Skip to content

Debt-to-assets at other companies

Eli Lilly logo
Eli LillyLLY
0.4×-0.1×
Amgen logo
AmgenAMGN
0.6×0.0×
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
0.0×
Immunome logo
ImmunomeIMNM
0.0×
Arcus Biosciences logo
Arcus BiosciencesRCUS
0.1×+0.1×
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
0.7×+0.2×

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.68B+81.4%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Calculated from Bicara Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's debt-to-assets?
Bicara Therapeutics (BCAX) reported debt-to-assets of 0× in Q1 2026.
How has Bicara Therapeutics's debt-to-assets changed year-over-year?
Bicara Therapeutics's debt-to-assets increased by 116.7% year-over-year, from 0× to 0×.
What is the long-term trend for Bicara Therapeutics's debt-to-assets?
Over 2 years (2023 to 2025), Bicara Therapeutics's debt-to-assets has grown at a 19.5% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.